Bronchodilators in heart failure patients with COPD: Is it time for a clinical trial?

Journal of Cardiac Failure

Volumn 18, Issue 5, 2012, Pages 413-422

  Mentz, Robert J ^a   Fiuzat, Mona ^a   Kraft, Monica ^a   Lindenfeld, Joann ^b   O'Connor, Christopher M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

anticholinergics; beta 2 agonists; COPD; heart failure

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; FORMOTEROL; IPRATROPIUM BROMIDE; LONG ACTING DRUG; SALBUTAMOL; SALMETEROL; TERBUTALINE; TIOTROPIUM BROMIDE;

CARDIOVASCULAR RISK; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DRUG ANTAGONISM; DRUG CHOICE; DRUG RESEARCH; DRUG SAFETY; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW;

BRONCHODILATOR AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HEART FAILURE; HUMANS; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84860433449     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2012.02.002     Document Type: Review

References (90)

1. E.P. Havranek, F.A. Masoudi, K.A. Westfall, P. Wolfe, D.L. Ordin, and H.M. Krumholz Spectrum of heart failure in older patients: results from the National Heart Failure project Am Heart J 143 2002 412 417
2. N.M. Hawkins, M.C. Petrie, P.S. Jhund, G.W. Chalmers, F.G. Dunn, and J.J. McMurray Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology Eur J Heart Fail 11 2009 130 139
3. C.M. O'Connor, W.T. Abraham, N.M. Albert, R. Clare, W. Gattis Stough, and M. Gheorghiade Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) Am Heart J 156 2008 662 673
4. N.M. Hawkins, D. Wang, M.C. Petrie, M.A. Pfeffer, K. Swedberg, and C.B. Granger Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme Eur J Heart Fail 12 2010 557 565
5. D.P. Tashkin, B. Celli, S. Senn, D. Burkhart, S. Kesten, and S. Menjoge A 4-year trial of tiotropium in chronic obstructive pulmonary disease N Engl J Med 359 2008 1543 1554
6. R.W. Light, and R.B. George Serial pulmonary function in patients with acute heart failure Arch Intern Med 143 1983 429 433
7. C.C. Naum, F.C. Sciurba, and R.M. Rogers Pulmonary function abnormalities in chronic severe cardiomyopathy preceding cardiac transplantation Am Rev Respir Dis 145 1992 1334 1338
8. L. Caruana, M.C. Petrie, A.P. Davie, and J.J. McMurray Do patients with suspected heart failure and preserved left ventricular systolic function suffer from "diastolic heart failure" or from misdiagnosis? A prospective descriptive study BMJ 321 2000 215 218
9. A.J. Singer, C. Emerman, D.M. Char, J.T. Heywood, J.D. Kirk, and J.E. Hollander Bronchodilator therapy in acute decompensated heart failure patients without a history of chronic obstructive pulmonary disease Ann Emerg Med 51 2008 25 34
10. P.M. Calverley, J.A. Anderson, B. Celli, G.T. Ferguson, C. Jenkins, and P.W. Jones Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease N Engl J Med 356 2007 775 789
11. S. Appleton, P. Poole, B. Smith, A. Veale, T.J. Lasserson, and M.M. Chan Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease Cochrane Database Syst Rev 3 2006 CD001104
12. R.A. Stockley, P.J. Whitehead, and M.K. Williams Improved outcomes in patients with chronic obstructive pulmonary disease treated with salmeterol compared with placebo/usual therapy: results of a meta-analysis Respir Res 7 2006 147
13. D.P. Tashkin Long-acting anticholinergic use in chronic obstructive pulmonary disease: efficacy and safety Curr Opin Pulm Med 16 2010 97 105
14. D.H. Au, R.N. Lemaitre, J.R. Curtis, N.L. Smith, and B.M. Psaty The risk of myocardial infarction associated with inhaled beta-adrenoceptor agonists Am J Respir Crit Care Med 161 2000 827 830
15. S.R. Salpeter, T.M. Ormiston, and E.E. Salpeter Cardiovascular effects of β-agonists in patients with asthma and COPD Chest 125 2004 2309 2321
16. S. Singh, Y.K. Loke, and C.D. Furberg Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis JAMA 300 2008 1439 1450
17. D.H. Au, E.M. Udris, V.S. Fan, J.R. Curtis, M.B. McDonell, and S.D. Fihn Risk of mortality and heart failure exacerbations associated with inhaled β-adrenoceptor agonists among patients with known left ventricular systolic dysfunction Chest 123 2003 1964 1969
18. N.M. Hawkins, M.C. Petrie, M.R. Macdonald, P.S. Jhund, L.M. Fabbri, and J. Wikstrand Heart failure and chronic obstructive pulmonary disease the quandary of beta-blockers and beta-agonists J Am Coll Cardiol 57 2011 2127 2138
19. M. Padeletti, S. Jelic, and T.H. LeJemtel Coexistent chronic obstructive pulmonary disease and heart failure in the elderly Int J Cardiol 125 2008 209 215
20. S. Salpeter, T. Ormiston, and E. Salpeter Cardioselective beta-blockers for chronic obstructive pulmonary disease Cochrane Database Syst Rev 4 2005 CD003566
21. L. Staszewsky, M. Wong, S. Masson, S. Barlera, E. Carretta, and A.P. Maggioni Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial J Card Fail 13 2007 797 804
22. D.D. Sin, and F.A. McAlister The effects of beta-blockers on morbidity and mortality in a population-based cohort of 11,942 elderly patients with heart failure Am J Med 113 2002 650 656
23. N.M. Hawkins, Z. Huang, K.S. Pieper, S.D. Solomon, L. Kober, and E.J. Velazquez Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT) Eur J Heart Fail 11 2009 292 298
24. T.H. le Jemtel, M. Padeletti, and S. Jelic Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure J Am Coll Cardiol 49 2007 171 180
25. J. Lindenfeld, N.M. Albert, J.P. Boehmer, S.P. Collins, J.A. Ezekowitz, and M.M. Givertz HFSA 2010 Comprehensive Heart Failure Practice Guideline J Card Fail 16 2010 e1 194
26. M. Egred, S. Shaw, B. Mohammad, P. Waitt, and E. Rodrigues Under-use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease QJM 98 2005 493 497
27. G.C. Fonarow, W.T. Abraham, N.M. Albert, W.G. Stough, M. Gheorghiade, and B.H. Greenberg Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program J Am Coll Cardiol 52 2008 190 199
28. J.B. Braunstein, G.F. Anderson, G. Gerstenblith, W. Weller, M. Niefeld, and R. Herbert Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure J Am Coll Cardiol 42 2003 1226 1233
29. C.T. Lien, N.D. Gillespie, A.D. Struthers, and M.E. McMurdo Heart failure in frail elderly patients: diagnostic difficulties, co-morbidities, polypharmacy and treatment dilemmas Eur J Heart Fail 4 2002 91 98
30. M.E. Tinetti, G.J. McAvay, S.S. Chang, A.B. Newman, A.L. Fitzpatrick, and T.R. Fried Contribution of Multiple Chronic Conditions to Universal Health Outcomes J Am Geriatr Soc 59 2011 1686 1691
31. M.H. van der Wal, T. Jaarsma, and D.J. van Veldhuisen Noncompliance in patients with heart failure; how can we manage it? Eur J Heart Fail 7 2005 5 17
32. GOLD Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: NHLBI/WHO workshop report 2006.
33. K.F. Rabe, S. Hurd, A. Anzueto, P.J. Barnes, S.A. Buist, and P. Calverley Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary Am J Respir Crit Care Med 176 2007 532 555
34. M.G. Matera, E. Martuscelli, and M. Cazzola Pharmacological modulation of beta-adrenoceptor function in patients with coexisting chronic obstructive pulmonary disease and chronic heart failure Pulm Pharmacol Ther 23 2010 1 8
35. R.D. Restrepo Use of inhaled anticholinergic agents in obstructive airway disease Respir Care 52 2007 833 851
36. D.E. Hilleman, M.A. Malesker, L.E. Morrow, and D. Schuller A systematic review of the cardiovascular risk of inhaled anticholinergics in patients with COPD Int J Chron Obstruct Pulmon Dis 4 2009 253 263
37. R.E. Ruffin, E.L. McIntyre, K.M. Latimer, H.E. Ward, A.J. Crockett, and J.H. Alpers Assessment of beta-adrenoceptor antagonists in asthmatic patients Br J Clin Pharmacol 13 1982 325S 335S
38. E.D. Bateman, S. Rennard, P.J. Barnes, P.V. Dicpinigaitis, R. Gosens, and N.J. Gross Alternative mechanisms for tiotropium Pulm Pharmacol Ther 22 2009 533 542
39. D.H. Au, E.M. Udris, J.R. Curtis, M.B. McDonell, and S.D. Fihn Association between chronic heart failure and inhaled β-2-adrenoceptor agonists Am Heart J 148 2004 915 920
40. Xamoterol in Severe Heart Failure Study Group Xamoterol in severe heart failure Lancet 336 1990 1 6
41. J. Vestbo The TORCH (Toward a Revolution in COPD Health) survival study protocol Eur Respir J 24 2004 206 210
42. A.A. Fisher, M.W. Davis, and D.A. McGill Acute myocardial infarction associated with albuterol Ann Pharmacother 38 2004 2045 2049
43. D.H. Au, J.R. Curtis, N.R. Every, M.B. McDonell, and S.D. Fihn Association between inhaled beta-agonists and the risk of unstable angina and myocardial infarction Chest 121 2002 846 851
44. S. Suissa, B. Hemmelgarn, L. Blais, and P. Ernst Bronchodilators and acute cardiac death Am J Respir Crit Care Med 154 1996 1598 1602
45. S.S. Coughlin, C. Metayer, E.P. McCarthy, F.J. Mather, R.E. Waldhorn, and B.J. Gersh Respiratory illness, beta-agonists, and risk of idiopathic dilated cardiomyopathy. The Washington, DC, Dilated Cardiomyopathy Study Am J Epidemiol 142 1995 395 403
46. R.N. Lemaitre, D.S. Siscovick, B.M. Psaty, R.M. Pearce, T.E. Raghunathan, and E.A. Whitsel Inhaled beta-2 adrenergic receptor agonists and primary cardiac arrest Am J Med 113 2002 711 716
47. T. Ringbaek, and K. Viskum Is there any association between inhaled ipratropium and mortality in patients with COPD and asthma? Respir Med 97 2003 264 272
48. T.A. Lee, A.S. Pickard, D.H. Au, B. Bartle, and K.B. Weiss Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease Ann Intern Med 149 2008 380 390
49. US Food and Drug Administration. Early communication about an ongoing safety review of tiotropium (marketed as Spiriva HandiHaler), 2008. Available at: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm070651.htm. Accessed February 24, 2012.
50. N.R. Anthonisen, J.E. Connett, P.L. Enright, and J. Manfreda Hospitalizations and mortality in the Lung Health Study Am J Respir Crit Care Med 166 2002 333 339
51. J.A. Wedzicha, P.M. Calverley, T.A. Seemungal, G. Hagan, Z. Ansari, and R.A. Stockley The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide Am J Respir Crit Care Med 177 2008 19 26
52. C. Macie, K. Wooldrage, J. Manfreda, and N. Anthonisen Cardiovascular morbidity and the use of inhaled bronchodilators Int J Chron Obstruct Pulmon Dis 3 2008 163 169
53. S.S. Ogale, T.A. Lee, D.H. Au, D.M. Boudreau, and S.D. Sullivan Cardiovascular events associated with ipratropium bromide in COPD Chest 137 2010 13 19
54. C. de Luise, S.F. Lanes, J. Jacobsen, L. Pedersen, and H.T. Sorensen Cardiovascular and respiratory hospitalizations and mortality among users of tiotropium in Denmark Eur J Epidemiol 22 2007 267 272
55. D.D. Sin, and J.V. Tu Lack of association between ipratropium bromide and mortality in elderly patients with chronic obstructive airway disease Thorax 55 2000 194 197
56. M. Jara, S.F. Lanes, C. Wentworth 3rd, C. May, and S. Kesten Comparative safety of long-acting inhaled bronchodilators: a cohort study using the UK THIN primary care database Drug Saf 30 2007 1151 1160
57. B. Celli, M. Decramer, I. Leimer, U. Vogel, S. Kesten, and D.P. Tashkin Cardiovascular safety of tiotropium in patients with COPD Chest 137 2010 20 30
58. S. Kesten, M. Jara, C. Wentworth, and S. Lanes Pooled clinical trial analysis of tiotropium safety Chest 130 2006 1695 1703
59. Y. Oba, T. Zaza, and D.M. Thameem Safety, tolerability and risk benefit analysis of tiotropium in COPD Int J Chron Obstruct Pulmon Dis 3 2008 575 584
60. C. Vogelmeier, B. Hederer, T. Glaab, H. Schmidt, M.P. Rutten-van Molken, and K.M. Beeh Tiotropium versus salmeterol for the prevention of exacerbations of COPD N Engl J Med 364 2011 1093 1103
61. B.A. Chowdhury, and G. Dal Pan The FDA and safe use of long-acting beta-agonists in the treatment of asthma N Engl J Med 362 2010 1169 1171
62. M. Bohm Alterations of beta-adrenoceptor-G-protein-regulated adenylyl cyclase in heart failure Mol Cell Biochem 147 1995 147 160
63. R.F. Schafers, S. Adler, A. Daul, G. Zeitler, M. Vogelsang, and H.R. Zerkowski Positive inotropic effects of the beta 2-adrenoceptor agonist terbutaline in the human heart: effects of long-term beta 1-adrenoceptor antagonist treatment J Am Coll Cardiol 23 1994 1224 1233
64. M. Mokry, P. Joppa, E. Slaba, J. Zidzik, V. Habalova, and Z. Kluchova Beta2-adrenergic receptor haplotype and bronchodilator response to salbutamol in patients with acute exacerbations of COPD Med Sci Monit 14 2008 CR392 CR398
65. N. Hizawa, H. Makita, Y. Nasuhara, T. Betsuyaku, Y. Itoh, and K. Nagai Beta2-adrenergic receptor genetic polymorphisms and short-term bronchodilator responses in patients with COPD Chest 132 2007 1485 1492
66. G.L. Braden, M.J. Germain, J.G. Mulhern, J.G. Hafer Jr., and W.F. Bria Hemodynamic, cardiac, and electrolyte effects of low-dose aerosolized terbutaline sulfate in asthmatic patients Chest 114 1998 380 387
67. N.G. Uren, S.W. Davies, S.L. Jordan, and D.P. Lipkin Inhaled bronchodilators increase maximum oxygen consumption in chronic left ventricular failure Eur Heart J 14 1993 744 750
68. J. Rossinen, J. Partanen, B. Stenius-Aarniala, and M.S. Nieminen Salbutamol inhalation has no effect on myocardial ischaemia, arrhythmias and heart-rate variability in patients with coronary artery disease plus asthma or chronic obstructive pulmonary disease J Intern Med 243 1998 361 366
69. T.M. Ng, M.A. Munger, W.L. Lombardi, T.H. Doing, D.T. Ryujin, and D.C. Young Chronically inhaled salmeterol improves pulmonary function in heart failure J Cardiovasc Pharmacol 40 2002 140 145
70. R. Slutsky Hemodynamic effects of inhaled terbutaline in congestive heart failure patients without lung disease: beneficial cardiotonic and vasodilator beta-agonist properties evaluated by ventricular catheterization and radionuclide angiography Am Heart J 101 1981 556 560
71. C.A. Maak, J.A. Tabas, and D.E. McClintock Should acute treatment with inhaled beta agonists be withheld from patients with dyspnea who may have heart failure? J Emerg Med 2008
72. Cardiac Arrhythmia Suppression Trial (CAST) Investigators Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction N Engl J Med 321 1989 406 412
73. G.M. Felker, and C.M. O'Connor Rational use of inotropic therapy in heart failure Curr Cardiol Rep 3 2001 108 113
74. J.F. Donohue, J.A. van Noord, E.D. Bateman, S.J. Langley, A. Lee, and T.J. Witek Jr. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol Chest 122 2002 47 55
75. V. Brusasco, R. Hodder, M. Miravitlles, L. Korducki, L. Towse, and S. Kesten Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD Thorax 58 2003 399 404
76. C.M. O'Connor, V. Hasselblad, R.H. Mehta, G. Tasissa, R.M. Califf, and M. Fiuzat Triage after hospitalization with advanced heart failure: the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) risk model and discharge score J Am Coll Cardiol 55 2010 872 878
77. N.C. Wang, A.P. Maggioni, M.A. Konstam, F. Zannad, H.B. Krasa, and J.C. Burnett Jr. Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction JAMA 299 2008 2656 2666
78. G. Torre-Amione, O. Milo-Cotter, E. Kaluski, L. Perchenet, I. Kobrin, and A. Frey Early worsening heart failure in patients admitted for acute heart failure: time course, hemodynamic predictors, and outcome J Card Fail 15 2009 639 644
79. G. Cotter, M. Metra, B.D. Weatherley, H.C. Dittrich, B.M. Massie, and P. Ponikowski Physician-determined worsening heart failure: a novel definition for early worsening heart failure in patients hospitalized for acute heart failure - association with signs and symptoms, hospitalization duration, and 60-day outcomes Cardiology 115 2010 29 36
80. B.M. Massie, C.M. O'Connor, M. Metra, P. Ponikowski, J.R. Teerlink, and G. Cotter Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure N Engl J Med 363 2010 1419 1428
81. M. Cazzola, and G. Novelli Biomarkers in COPD Pulm Pharmacol Ther 23 2010 493 500
82. A.S. Maisel, P. Krishnaswamy, R.M. Nowak, J. McCord, J.E. Hollander, and P. Duc Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure N Engl J Med 347 2002 161 167
83. J.L. Januzzi, R. van Kimmenade, J. Lainchbury, A. Bayes-Genis, J. Ordonez-Llanos, and M. Santalo-Bel NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP study Eur Heart J 27 2006 330 337
84. P.A. McCullough, J.E. Hollander, R.M. Nowak, A.B. Storrow, P. Duc, and T. Omland Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department Acad Emerg Med 10 2003 198 204
85. E. Bozkanat, E. Tozkoparan, O. Baysan, O. Deniz, F. Ciftci, and M. Yokusoglu The significance of elevated brain natriuretic peptide levels in chronic obstructive pulmonary disease J Int Med Res 33 2005 537 544
86. L. Cabanes, B. Richaud-Thiriez, Y. Fulla, F. Heloire, C. Vuillemard, and S. Weber Brain natriuretic peptide blood levels in the differential diagnosis of dyspnea Chest 120 2001 2047 2050
87. F.H. Rutten, M.J. Cramer, N.P. Zuithoff, J.W. Lammers, W. Verweij, and D.E. Grobbee Comparison of B-type natriuretic peptide assays for identifying heart failure in stable elderly patients with a clinical diagnosis of chronic obstructive pulmonary disease Eur J Heart Fail 9 2007 651 659
88. L.K. Morrison, A. Harrison, P. Krishnaswamy, R. Kazanegra, P. Clopton, and A. Maisel Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea J Am Coll Cardiol 39 2002 202 209
89. F.J. Martinez, J.F. Donohue, and S.I. Rennard The future of chronic obstructive pulmonary disease treatment - difficulties of and barriers to drug development Lancet 378 2011 1027 1037
90. J.T. Huang, R. Chaudhuri, O. Albarbarawi, A. Barton, C. Grierson, and P. Rauchhaus Clinical validity of plasma and urinary desmosine as biomarkers for chronic obstructive pulmonary disease Thorax 2012